Filtered By:
Specialty: Cancer & Oncology
Drug: Rituxan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 320 results found since Jan 2013.
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital
CONCLUSION: CRT may be omitted in patients with a negative end of treatment PET scans; however, careful observation may also obviate the need for CRT in PET positive patients.PMID:37734988 | DOI:10.1016/j.clml.2023.08.021
Source: Clinical Lymphoma and Myeloma - September 21, 2023 Category: Cancer & Oncology Authors: Su Li Bhupinder Sharma Siraj Yusuf Vasiliki Michalarea Mary Gleeson Laura Hickmott Andrew Wotherspoon Ayoma D Attygalle Katherine Vroobel Simon O'Connor Yong Du Andrea Kuhnl Sunil Iyengar Dima El-Sharkawi Ian Chau David Cunningham Source Type: research
Synchronous rectal adenocarcinoma and intestinal mantle cell lymphoma: A case report
CONCLUSION: Synchronous rectal adenocarcinoma and intestinal MCL presenting as multiple lymphomatous polyposis are extremely rare. MCL is often discovered fortuitously when rectal cancer is diagnosed. The coexistence of these tumors poses treatment challenges.PMID:37727717 | PMC:PMC10506007 | DOI:10.12998/wjcc.v11.i24.5772
Source: Clinical Colorectal Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Kim-Van Vu Nguyen-Van Trong Nguyen-Thi Khuyen Do Huyen Nga Hoang Anh Nguyen Tien Trung Pham Trung Thong Nguyen Minh Duc Source Type: research
Updates in the Management of Primary Mediastinal B Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under i...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Charbel Soueidy Hampig Raphael Kourie Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
Multiple sclerosis is associated with worse COVID-19 outcomes compared to the general population: A population-based study
CONCLUSION: This study revealed higher odds of hospitalization and mortality due to COVID-19 among PLWMS in comparison to age- and sex-matched controls from the general population. Nevertheless, it remains unclear whether the elevated odds are directly associated with MS itself or if they are influenced by factors such as rituximab using, comorbidity, and disease severity.PMID:37659351 | DOI:10.1016/j.msard.2023.104947
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Mahdi Barzegar Setayesh Sindarreh Amirreza Manteghinejad Omid Mirmosayyeb Shahrbanoo Mazaheri Maryam Rahimi Shaghayegh Haghjooy Javanmard Vahid Shaygannejad Maryam Nasirian Source Type: research
Trends in non-Hodgkin lymphoma mortality rate in Japan and the United States: A population-based study
Cancer Sci. 2023 Aug 18. doi: 10.1111/cas.15926. Online ahead of print.ABSTRACTCharacterizing trends in mortality rates with consideration of trends in incidence rates at the population level could help identify unmet needs in public health and provide essential indicators of cancer control. In the late 20th century, the arrival of the first molecular targeted agent, rituximab, for non-Hodgkin lymphoma (NHL) led to a paradigm shift in NHL treatment. However, the public health impact of this arrival has not been fully clarified. Here, we evaluated trends in the mortality and incidence rates of NHL in Japan and the United St...
Source: Cancer Control - August 18, 2023 Category: Cancer & Oncology Authors: Yoshiaki Usui Hidemi Ito Kota Katanoda Tomohiro Matsuda Yoshinobu Maeda Keitaro Matsuo Source Type: research
On the Precipice of a "Rituximab-Like" Era for T-cell Lymphomas?
Clin Cancer Res. 2023 Aug 15:CCR-23-1571. doi: 10.1158/1078-0432.CCR-23-1571. Online ahead of print.ABSTRACTTo date monoclonal antibodies have had limited success in improving outcomes for patients with T-cell lymphomas. Preclinical data suggests that anti-T-cell Receptor Vβ-segment monoclonal antibodies are a novel therapeutic strategy for patients with T-cell lymphomas that avoid several limitations of current therapies.PMID:37581573 | DOI:10.1158/1078-0432.CCR-23-1571
Source: Clinical Cancer Research - August 15, 2023 Category: Cancer & Oncology Authors: Gaurav Varma Catherine S Diefenbach Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Breast Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Breast Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
